This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF
catalog :
2078-T4
quantity :
50 ug
price :
349 USD
citations: 1
Reference
Lichterfeld M, Kavanagh D, Williams K, Moza B, Mui S, Miura T, et al. A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. J Exp Med. 2007;204:2813-24 pubmed
product information
brand :
R&D Systems
master code :
2078-T4
SKU :
2078-T4-050
product name :
Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF
description :
The Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF from R&D Systems is derived from NS0. The Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera Protein, CF has been validated for the following applications: Bioactivity.
target :
ILT4/CD85d/LILRB2
category :
Proteins and Enzymes
unit size :
50 ug
buffer :
Lyophilized from a 0.2 µm filtered solution in PBS.
conjugate :
Unconjugated
purity :
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
species :
Human
observed molecular weight :
94-100 kDa, reducing conditions
theoretical molecular weight :
73.9 kDa (monomer)
gene symbol :
LILRB2
details of functionality :
Measured by its binding ability in a functional ELISA. When Recombinant Human Angiopoietin-like Protein 5/ANGPTL5 (Catalog # 6675-AN ) is coated at 4 µg/mL, Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera binds with a typical ED50 of 0.15-0.9 µg/mL. Measured by its ability to support the adhesion of HSB2 human peripheral blood acute lymphoblastic leukemia cells. Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera immobilized at 35 µg/mL, 100 µL/well, will mediate 40% HSB-2 cell adhesion (105 cells/well).
endotoxin note :
<0.10 EU per 1 µg of the protein by the LAL method.
catalog number base :
2078-T4
accessionNumbers :
Q8N423
applications :
Bioactivity
source :
Mouse myeloma cell line, NS0-derived human LILRB2/CD85d/ILT4 protein Human LILRB2/CD85d/ILT4 (Gly24-His458) Accession # Q8N423 IEGRMD Human IgG1 (Pro100-Lys330) N-terminus C-terminus
2020 USD :
349
2021 USD :
349 USD
alt names :
CD85 antigen-like family member D, CD85d, CD85d antigen, Ig-like transcript 4, ILT4, ILT-4, ILT4CD85d, Immunoglobulin-like transcript 4, Leukocyte immunoglobulin-like receptor 2, leukocyte immunoglobulin-like receptor subfamily B member 2, leukocyte immunoglobulin-like receptor subfamily B member 2 soluble isoform, leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), LIR2, LIR2CD85D, LIR-2subfamily A (with TM domain), member 6, member 2, MIR10, MIR10LILRA6, Monocyte/macrophage immunoglobulin-like receptor 10
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.